Agomab’s ALK5 inhibitor has proven its ability to target the correct part of the intestine in a phase 2 trial of ...

MyHealthTeam, a Swoop company, the creator of one of the largest, engaged patient social networks in healthcare, has ...

Agomab Therapeutics NV (‘Agomab’) today announced positive interim results from 44 patients completing treatment in the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal ...

There are two main forms: Crohn s disease, which can affect the entire gastrointestinal tract, but is most common in the colon and terminal ileum; and ulcerative colitis, which is a mucosal ...